Jeffrey L. Cummings, MD, is currently Director of both the Deane F. Johnson Center for Neurotherapeutics at UCLA, and the UCLA Alzheimer's Disease Center. He holds the Augustus Rose Professor of Neurology chair, was the Shrinavasan Lecturer in 2004 and the Henderson Lecturer in 2005.

"Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed."

• Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.

Jeffrey L. Cummings, MD, is currently Director of both the Deane F. Johnson Center for Neurotherapeutics at UCLA, and the UCLA Alzheimer's Disease Center. He holds the Augustus Rose Professor of Neurology chair, was the Shrinavasan Lecturer in 2004 and the Henderson Lecturer in 2005.

"Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed."

• Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.

Jeffrey L. Cummings, MD, is currently Director of both the Deane F. Johnson Center for Neurotherapeutics at UCLA, and the UCLA Alzheimer's Disease Center. He holds the Augustus Rose Professor of Neurology chair, was the Shrinavasan Lecturer in 2004 and the Henderson Lecturer in 2005.

"Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed."

• Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.